Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab Combined With Decitabine/Venetoclax for TP53-mutated/Deleted AML
NCT07511062Phase 1Not yet recruiting
- Sponsor
- Northside Hospital
- Start
- Jan 2027
- Primary completion
- Aug 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of axatilimab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Northside Hospital. Primary endpoints: Recommended Phase 2 Dose at 1 year and Minimal Residual Disease-negative Complete Remission at 2 months. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
axatilimab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07511062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511062.